China biotech policy debate moves to Washington for live discussion

Endpoints News brought its ongoing China biotech debate to the nation’s capital, arranging a live session with officials shaping upcoming regulations.

The event featured interviews with several policymakers who are drafting new laws aimed at addressing the complexities of biotech development in China.

Participants discussed challenges such as data sharing, clinical trial standards, and market access, highlighting the need for clearer guidance.

The discussion underscored that while solutions are not yet finalized, the dialogue marks a step toward more coordinated international biotech policy.

Overall, the Washington session provided a platform for stakeholders to voice concerns and propose pathways forward.